Introduction
Although comparatively rare in Europe, hepatocellular carcinoma (HCC) is estimated to account for one million deaths worldwide each year.' There is evidence that the occurrence is increasing in both western Europe and in the USA. At present only surgical resection or transplantation offer the prospect oflong-term survival. Careful patient selection is crucial in resection, as survival in cirrhotic patients is significantly worse,2 and as a result the resectability rate in HCC may be as low as 1%.3 Over 75% ofpatients transplanted for HCC will be dead within 3 years, the vast majority from tumour recurrence. 4 For those patients with an irresectable tumour the prognosis is bleak, survival for more than 6 months being exceptional.5 A variety of nonsurgical treatments has been claimed to be of palliative benefit, including devascularization techniques, chemotherapy (used individually or in combination), cryotherapy and alcohol injection. There is, however, little evidence that any significantly improve survival.
We report a case of hepatocellular carcinoma treated with '311-lipiodol, a new tumour-selective agent, in which histological evidence of complete tumour ablation was obtained. (Figure 1 ). Gamma scintigraphy performed at 2 and 9 days confirmed retention of activity at the site of the tumour. The volumes of the tumour nodules were calculated from the CT scan using the formula Volume = maximum tumour diameter x perpendicular diameter2
Correspondence: J.R. Novell (Figure 3a) . On repeat scanning 6 months later the lesion is unchanged (Figure 3b) ; ultrasound scanning has shown regen- Our own experience in 8 patients to date has confirmed these findings. '3 To date there have been no reports of total tumour ablation using radioactive lipiodol. In this case, while the original malignant foci were rendered completely necrotic after treatment, the persistence of a raised serum AFP has raised the possibility of residual tumour. However, the patient remains asymptomatic and neither repeated CT scans, with and without Lipiodol enhancement, nor ultrasound scanning have demonstrated a further malignant focus. Persistent elevation in serum AFP has been documented after curative hepatic resection, and may be related to regenerative nodules in the cirrhotic liver. '4 This case demonstrates that '3'I-lipiodol is mapable of delivering an ablation dose of radiation to small foci of hepatocellular carcinoma. Lipiodol-targeted radiotherapy may be the treatment of choice for small tumours in older, cirrhotic patients who are at high risk of complications following surgical resection.
